To The Moon

As the IPO market gradually recovers in 2025, global investors have turned their attention to 2026, a year that could define the next decade. Among the many emerging tech giants rumored to be going public, two names consistently dominate the headlines: SpaceX, the space exploration company founded by Elon Musk, and OpenAI, the AI revolution spearheaded by Sam Altman. They are not only symbols of cutting-edge technology but also have the potential to become the largest IPOs in history. If both companies do go public in the same year, how should investors choose? 🚀 SpaceX: Packing the Interstellar Future into its Prospectus Founded in 2002 by serial entrepreneur Elon Musk, SpaceX aims to reduce launch costs through reusable rocket technology, with the ultimate goal of achieving travel to the

As the legendary era of the "Oracle of Omaha," Warren Buffett, draws to a close, his successor, Greg Abel, has officially been CEO of Berkshire Hathaway $Berkshire Hathaway(BRK.A)$ for just a month. Yet, a major move seems to be quietly brewing—one that could signal a rewrite of the company's long-standing investment philosophy. Recently, a regulatory filing stirred the market like a stone thrown into a calm lake: Berkshire may be preparing to sell its entire stake in Kraft Heinz $The Kraft Heinz Company(KHC)$ . Could this be the first defining moment of the "Post-Buffett Era"? ⚠️ An Unusual Risk Warning On Tuesday, food giant $The Kraft Heinz Company(KHC)$ incl

Since the start of 2025, the silver market has staged a spectacular rally. By the end of December 2025, silver prices had accumulated a staggering gain of approximately 171%. During the session on December 26, prices briefly touched a high of $80 per ounce before closing the year at around $72. Entering 2026, $iShares Silver Trust(SLV)$ continues to lead the commodities pack, emerging as the brightest performing asset in the Bloomberg Commodity Index. Meanwhile, the Gold-Silver Ratio—which measures how many ounces of silver it takes to buy one ounce of gold—has rapidly slid from recent highs to around 57. This is not only far below the long-term average of 68 but also marks a new low since 2013, signaling a strong "catch-up" momentum for silver rel

As spot gold prices forcefully break through$4,600 per ounce and continue to climb, multiple major institutions have set their sights on a target of $5,000 within the year. Driven by a combination of geopolitical risks, shifts in global monetary policy, and sustained central bank buying, the upward momentum for gold has been significantly reinforced.For investors looking to capitalize on this trend, buying physical gold isn't the only option. A selection of gold mining companies—characterized by solid fundamentals, production growth, and financial stability—offers a tool with greater leverage to play this rally.The following industry-leading companies are well-positioned to benefit directly from rising gold prices, each representing different regions, business models, and growth paths:1. <

Although high-valuation stocks in the current U.S. stock market continue to rise, and value stocks have lagged far behind growth stocks in recent years, stock valuations are still crucial for investors. Specifically in the medical sector, although the performance of U.S. medical stocks in the past two years has not been outstanding, the valuation is also lower than the $.SPX(.SPX)$ index. As market expectations for the medical sector improve, the industry will also regain the favor of value investors.Looking ahead to the next five years, the following two U.S. medical value stocks are expected to shine.U.S. medical value stocks 1: $Moderna, Inc.(MRNA)$ Moderna has become a household name for developing an

It’s no secret that big pharmaceutical companies like $Eli Lilly(LLY)$ need to get regulators to agree that their drugs are safe and effective before they can make money. But regulators aren’t the only group companies need to appease before shareholders see returns.On October 23, Eli Lilly’s Alzheimer’s drug Kisunla was approved in the UK by the Medicines and Healthcare Products Regulatory Agency (MHRA), following in the footsteps of the US Food and Drug Administration (FDA) and Japanese regulators. UK regulators agreed with clinical trial results that showed the drug was somewhat effective in slowing or stopping the rate of cognitive decline associated with the disease for up to about seven months. They also found that treatment-related side effects,

$GLOBAL X DOW 30® COVERED CALL ETF(DJIA)$ is unique, featuring only 30 stocks and being a price-weighted index. As one of the major U.S. stock indices, it offers a solid starting point for dividend stock investors, including strategies like buying the top 10 highest-yielding stocks, often referred to as "Dogs of the Dow."Currently, the top three dividend-paying stocks in the Dow are $Verizon(VZ)$ $Dow Chemical(DOW)$ $Chevron(CVX)$. These companies offer attractive dividends, but it's essential to consider their individual risk factors before diving in.1. $Verizon(VZ)$ : A Key Player w

In August 2011, just a few years after the financial crisis, Standard & Poor’s downgraded the U.S. credit rating from AAA (the highest rating) to AA+ (the second highest). Then, in August 2023, Fitch followed suit, lowering the U.S. from AAA to AA+. Both S&P and Fitch still see the U.S. as having an extremely low risk of default, but that top-tier status is undeniably gone.Many U.S. companies have faced a similar fate. Back in 1980, around 60 publicly traded companies held AAA credit ratings. After more than four decades of acquisitions, mergers, bankruptcies, innovation, and economic shifts, only two companies still hold this perfect rating: tech giant $Microsoft(MSFT)$ and healthcare powerhouse $John

In the stock market, you don’t need to bet everything on expensive stocks to invest in quality companies. There are still solid options available at reasonable prices, like $Exelixis(EXEL)$ , which is currently trading below $40.Major Wins for ExelixisExelixis is a biotechnology company focused on oncology, with its most important product being Cabometyx, used to treat renal cell carcinoma (a type of kidney cancer) and hepatocellular carcinoma (liver cancer).Cabometyx has been the cornerstone of Exelixis’s revenue for some time. In Q2, its revenue grew 35.6% year-over-year, reaching $637.2 million. Cabometyx alone accounted for $437.6 million in the U.S., making up nearly 69% of the company's total revenue.While relying heavily on one product carr

On October 30, $Meta Platforms, Inc.(META)$ will release its Q3 2024 earnings report. Overall, the results are expected to be solid, offering enough reasons for the stock to maintain its strength—at least on the surface.But beyond logic, other forces are driving the stock and market. Even though Meta might continue showing decent relative growth, analysts aren’t optimistic about further gains. Why? Revenue growth is slowing, expenses are rising, and the stock is already hitting record highs.2025 Outlook: AI Investments and Growth SlowdownOnce 2025 comes into focus and massive AI investments start weighing on the balance sheet, things won’t be so easy. Revenue growth is naturally slowing after the strong gains of the past two years. Meta’s path for